A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.

Key facts

Study ID

NCT05549505

Run by

Arvinas Inc.

People needed

152

Starts

2023-02-15

Expected to finish

2024-07-25

Last updated by the study team

2025-08-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Post-menopausal females ≥ 18 years.
• Histologically or cytologically confirmed ER+ and HER2- breast cancer (per local assessment). ER and HER2 status must be documented:
• ER+ disease, with ER staining of ≥ 10% of tumor cell nuclei by immunohistochemistry (IHC) per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
• HER2- disease by either IHC or in situ hybridization per ASCO/CAP guidelines.
• Ki-67 score ≥ 5%, analyzed locally.
• Clinical T1c-T4c, N0-N2, M0 breast cancer amenable to definitive surgical resection, without bilateral breast ductal carcinoma in situ or invasive breast cancer.
• The primary tumor must be at least 1.5 cm by imaging.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Willingness to undergo a screening biopsy, an on-treatment biopsy and surgical resection.

You may not qualify if…

• Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or cervical carcinoma in situ.
• Any of the following in the previous 6 months: Myocardial infarction; Severe unstable angina; Coronary/peripheral artery bypass graft; Symptomatic congestive heart failure (New York Heart Association class III or IV); Cerebrovascular accident; Transient ischemic attack; Symptomatic pulmonary embolism or other clinically significant episode of thromboembolism.
• Any of the following in the previous 6 months: Congenital long QT syndrome; Torsade de Pointes; Sustained ventricular tachyarrhythmia and ventricular fibrillation; Left anterior hemiblock (bifascicular block); Ongoing cardiac dysrhythmias of NCI CTCAE ≥ Grade 2; Atrial fibrillation of any grade (≥ Grade 2 in the case of asymptomatic lone atrial fibrillation).
• corrected QT (Fridericia method) (QTcF) > 470 msec.
• Active, uncontrolled bacterial, fungal or viral infection, including (but not limited to) hepatitis B virus (HBV), hepatitis C virus (HCV), and known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
• Active inflammatory gastrointestinal disease, chronic diarrhea, known uncontrolled diverticular disease, or previous gastric resection or lap band surgery.
• Cirrhosis meeting criteria for Child Pugh B and C.
• Prior treatment for breast cancer including systemic therapy (eg, chemotherapy, hormonal therapy), radiation, surgery, or any investigational agents.
• Any live vaccines within 14 days of planned start of first dose of study drug.
• Major surgery (as defined by the Investigator) within four weeks of first dose of study drug.

Where it is running

• Clinical Trial Site — Springdale, Arkansas, United States
• Clinical Trial Site — Los Angeles, California, United States
• Clinical Trial Site — Torrance, California, United States
• Clinical Trial Site — Van Nuys, California, United States
• Clinical Trial Site — Fort Lauderdale, Florida, United States
• Clinical Trial Site — Fort Myers, Florida, United States
• Clinical Trial Site — Orlando, Florida, United States
• Clinical Trial Site — West Palm Beach, Florida, United States
• Clinical Trial Site — Iowa City, Iowa, United States
• Clinical Trial Site — Springfield, Massachusetts, United States
• Clinical Trial Site — St Louis, Missouri, United States
• Clinical Trial Site — Nashville, Tennessee, United States
• Clinical Trial Site — Tacoma, Washington, United States
• Clinical Trial Site — Batumi, Georgia
• Clinical Trial Site — Tbilisi, Georgia
• Clinical Trial Site — Tbilisi, Georgia
• Clinical Trial Site — Tbilisi, Georgia
• Clinical Trial Site — Augsburg, Germany
• Clinical Trial Site — Berlin, Germany
• Clinical Trial Site — Bonn, Germany
• Clinical Trial Site — Bottrop, Germany
• Clinical Trial Site — Chemnitz, Germany
• Clinical Trial Site — Dresden, Germany
• Clinical Trial Site — Erlangen, Germany
• Clinical Trial Site — Essen, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.